Nomoto Asuka, Suzuki Yui, Morito Katsuya, Nagasawa Kazuki, Takayama Kentaro
Laboratory of Environmental Biochemistry, Kyoto Pharmaceutical University, 5 Misasaginakauchi-cho, Yamashina, Kyoto 607-8414, Japan.
ACS Med Chem Lett. 2024 Feb 14;15(3):376-380. doi: 10.1021/acsmedchemlett.3c00541. eCollection 2024 Mar 14.
Neuromedin U receptor 2 (NMUR2), which is expressed in the central nervous system (CNS) including the hypothalamus, has been noted as a therapeutic target against obesity. We previously reported that intranasal administration of CPN-219, a NMUR2-selective hexapeptide agonist, suppresses body weight gain in mice; however, there is no detailed information regarding its CNS effects. Recently, in addition to appetite suppression, stress responses and regulation of prolactin (PRL) secretion have also attracted attention. NMUR2 expressed in the hypothalamic tuberoinfundibular dopaminergic neurons has emerged as an alternative target for treating hyperprolactinemia. Here, CPN-219 decreased food intake up to 24 h after administration at a dose of 200 nmol, resulting in body weight gain suppression, although grooming and anxiety-like behaviors were transiently induced. Interestingly, the restraint stress-induced increase in plasma PRL levels was significantly suppressed at a lower dose of 20 nmol, indicating the potential for drug development as an anti-PRL agent of NMUR2-selective agonists.
神经介素U受体2(NMUR2)在下丘脑等中枢神经系统(CNS)中表达,已被视为对抗肥胖的治疗靶点。我们之前报道过,鼻内给予NMUR2选择性六肽激动剂CPN - 219可抑制小鼠体重增加;然而,关于其对中枢神经系统的影响尚无详细信息。最近,除了食欲抑制外,应激反应和催乳素(PRL)分泌的调节也受到了关注。在下丘脑结节漏斗多巴胺能神经元中表达的NMUR2已成为治疗高催乳素血症的另一个靶点。在此,CPN - 219在剂量为200 nmol时给药后24小时内可减少食物摄入量,导致体重增加受到抑制,尽管梳理毛发和焦虑样行为会被短暂诱导。有趣的是,在较低剂量20 nmol时,束缚应激诱导的血浆PRL水平升高被显著抑制,这表明NMUR2选择性激动剂作为抗PRL药物具有药物开发潜力。